If this conclusion is accurate, then it would indicate a possible target for future research on chronic treatment with TRPV1 agonists in the diabetic and obesity conditions, evaluating whether these agonists could attenuate or prevent vascular dysfunction. This evidence concerns the gene TRPV1 and obesity disorder.